Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis

MASAYUKI NAKASHIMA; MASATO TAKEUCHI; SHIRO TANAKA; KOJI KAWAKAMI

doi:10.21873/anticanres.14862

Abstract

Background/aim: This study aimed to describe the chemotherapy effects after trifluridine/tipiracil (TFTD) and/or regorafenib treatment in colorectal cancer (CRC) patients. Patients and Methods: Patients receiving regorafenib or TFTD for metastatic CRC during 2013-2018 were selected and divided into two groups: one with additional chemotherapy after regorafenib or TFTD (CTX group) and one without additional chemotherapy (Non-CTX group). Patients were followed up from a landmark point (90 days from the last day of administration of regorafenib or TFTD). We compared overall survival (OS) between the groups. Results: The median OS was 7.7 months in the CTX group and 4.1 months in the non-CTX groups. Several sensitivity analyses did not negate the survival advantage detected in the CTX group. Conclusion: The chemotherapy after regorafenib or TFTD was associated with prolonged OS in advanced CRC patients. Further study is required to determine appropriate treatment choice.

Key Words:

Footnotes

Authors’ Contributions
Conception/design: Masayuki Nakashima, Masato Takeuchi, Koji Kawakami. Collection and/or assembly of data: Masayuki Nakashima. Data analysis and interpretation: Masayuki Nakashima, Masato Takeuchi, Shiro Tanaka, Koji Kawakami. Manuscript writing: Masayuki Nakashima, Masato Takeuchi. Final approval of manuscript: Masayuki Nakashima, Masato Takeuchi, Shiro Tanaka, Koji Kawakami.
Conflicts of Interest
K.K. received advisory fee from Shin Nippon Biomedical Laboratories, Ltd, Japan, JMDC Inc., Japan, AGREE Inc., Japan; research funds from Sumitomo Dainippon Pharma Co, Ltd, Japan, Pfizer Inc., Japan, Stella Pharma Corporation, Japan, CMIC Co, Ltd, Japan, Suntory Beverage & Food Ltd, Japan, Medical Platform Co, Ltd, Japan, and Real World Data, Co, Ltd., Japan; and holds stocks of Real World Data, Co, Ltd., Japan. There are no patent products under development or marketed products to declare, relevant to these companies. The remaining Authors have stated that they have no conflicts of interest.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Received December 23, 2020.
Revision received January 8, 2021.
Accepted January 12, 2021.

View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.